**Supplementary Table S7**

Supplementary Table S11: Comparison of PBMC subsets (major subsets, CD4 subsets, CD8 subsets, Tregs, and T-cell activation status) and plasma immune response and checkpoint markers between the fit and frail patients at baseline. The number of measurements (N), median, interquartile range (IQR), raw P-values, and FDR-corrected p-values are reported. The P-values were calculated using an unpaired Mann-Whitney U test. The P-values below the significance threshold of 5% are indicated in bold italics. FDR: false discovery rate; MFI: mean fluorescence intensity.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Biomarker** | **Fit** | | **Frail** | | ***P*-values** | |
| **N** | **Median [IQR]** | **N** | **Median [IQR]** | **Raw** | **FDR** |
| **PBMC - Major Subsets** |  |  |  |  |  |  |
| Viable cells (% of total cells) | 8 | 99.20 [96.94;99.51] | 12 | 98.65 [98.29;99.18] | 0.232 | 0.596 |
| Viable lymphocytes (% of total lymphocytes) | 8 | 98.12 [96.27;98.48] | 12 | 96.73 [90.71;97.76] | 0.154 | 0.531 |
| Total T-cells (% of viable lymphocytes) | 8 | 61.50 [56.82;71.20] | 12 | 62.16 [53.54;64.67] | 0.643 | 0.930 |
| Total T-cells (% of viable cells) | 8 | 59.39 [42.18;64.59] | 12 | 54.68 [47.77;61.56] | 0.908 | 0.969 |
| CD4+ T-cells (% of viable lymphocytes) | 8 | 52.70 [29.20;56.34] | 12 | 50.22 [44.03;57.76] | 0.671 | 0.930 |
| CD8+ T-cells (% of viable lymphocytes) | 8 | 16.44 [14.48;20.99] | 12 | 13.96 [8.49;18.23] | 0.177 | 0.531 |
| CD4/CD8 ratio (% CD4/CD8 ratio) | 8 | 3.16 [1.60;4.12] | 12 | 3.99 [2.61;6.86] | 0.154 | 0.531 |
| NK/T-cells (% of viable cells) | 8 | 4.46 [2.65;10.06] | 12 | 1.81 [1.43;3.70] | ***0.049*** | 0.442 |
| Total NK cells (% of viable cells) | 8 | 9.16 [5.54;12.23] | 12 | 6.52 [3.69;10.64] | 0.375 | 0.836 |
| CD56 bright CD16- (% of total NK cells) | 8 | 3.96 [2.64;12.78] | 12 | 4.74 [4.00;8.47] | 0.563 | 0.921 |
| CD56 dim CD16+ (% of total NK cells) | 8 | 82.71 [68.17;91.11] | 12 | 58.52 [19.32;76.44] | ***0.015*** | 0.272 |
| Total B-cells (% of viable cells) | 8 | 9.00 [7.47;10.06] | 12 | 7.51 [5.58;9.54] | 0.418 | 0.836 |
| Naive B-cells (% of total B-cells) | 8 | 58.95 [54.53;71.71] | 12 | 62.99 [42.09;75.50] | 0.969 | 0.969 |
| Memory B-cells (% of total B-cells) | 8 | 40.22 [27.47;44.21] | 12 | 35.87 [23.20;56.53] | 0.969 | 0.969 |
| Total monocytes (% of viable cells) | 8 | 13.77 [12.65;16.06] | 12 | 18.11 [8.34;24.38] | 0.512 | 0.921 |
| Non-classical monocytes (% of total monocytes) | 8 | 4.47 [3.04;5.03] | 12 | 3.41 [1.19;9.72] | 0.969 | 0.969 |
| Intermediate monocytes (% of total monocytes) | 8 | 5.76 [4.17;6.75] | 12 | 6.17 [4.74;7.32] | 0.787 | 0.969 |
| Classical monocytes (% of total monocytes) | 8 | 83.73 [80.18;86.12] | 12 | 79.92 [68.76;83.23] | 0.154 | 0.531 |
| **PBMC - CD4 Subsets** |  |  |  |  |  |  |
| Naïve CD4+ (% of CD4+ T-cells) | 8 | 26.32 [18.89;49.10] | 12 | 44.61 [22.85;50.60] | 0.335 | 0.567 |
| CD27 expression in Naïve CD4+ (MFI) | 8 | 1458.50 [1248.50;1752.50] | 12 | 1312.00 [914.50;1596.50] | 0.232 | 0.497 |
| CD28 expression in Naïve CD4+ (MFI) | 8 | 766.00 [666.00;864.00] | 12 | 614.00 [548.50;726.50] | 0.203 | 0.497 |
| Naïve CD4+ CD27+ CD28+ (% of Naïve CD4+ T-cells) | 8 | 96.01 [90.34;98.05] | 12 | 88.82 [71.31;92.93] | ***0.019*** | 0.307 |
| CD27 expression in Naïve CD4+ CD27+CD28+ (MFI) | 8 | 1491.00 [1323.50;1831.50] | 12 | 1424.50 [1134.00;1677.50] | 0.464 | 0.567 |
| CD28 expression in Naïve CD4+ CD27+CD28+ (MFI) | 8 | 764.00 [690.50;871.00] | 12 | 649.50 [565.50;739.50] | 0.177 | 0.497 |
| Naïve CD4+ CD57+ (% of Naïve CD4+ T-cells) | 8 | 4.70 [2.43;18.71] | 12 | 2.68 [1.35;11.63] | 0.563 | 0.641 |
| CM CD4+ (% of CD4+ T-cells) | 8 | 60.90 [39.22;66.37] | 12 | 47.86 [33.74;59.69] | 0.203 | 0.497 |
| CD27 expression in CM CD4+ (MFI) | 8 | 1279.00 [970.00;1521.00] | 11 | 1006.00 [817.00;1326.00] | 0.231 | 0.497 |
| CD28 expression in CM CD4+ (MFI) | 8 | 1265.00 [1068.50;1379.00] | 12 | 1089.50 [868.00;1247.50] | 0.133 | 0.497 |
| CM CD4+ CD27+ CD28+ (% of CM CD4+ T-cells) | 8 | 80.46 [74.87;83.76] | 12 | 70.12 [59.29;79.39] | 0.114 | 0.497 |
| CD27 expression in CM CD4+ CD27+CD28+ (MFI) | 8 | 1490.00 [1261.50;1803.00] | 12 | 1359.50 [1183.50;1601.00] | 0.375 | 0.567 |
| CD28 expression in CM CD4+ CD27+CD28+ (MFI) | 8 | 1227.50 [1092.50;1347.00] | 12 | 1111.00 [888.50;1256.50] | 0.217 | 0.497 |
| CM CD4+ CD57+ (% of CM CD4+ T-cells) | 8 | 2.01 [1.53;3.10] | 12 | 2.87 [1.96;4.05] | 0.232 | 0.497 |
| EM CD4+ (% of CD4+ T-cells) | 8 | 10.51 [6.97;18.67] | 12 | 10.35 [5.42;14.76] | 0.464 | 0.567 |
| CD27 expression in EM CD4+ (MFI) | 8 | 456.00 [322.50;505.00] | 11 | 371.00 [134.00;579.00] | 0.536 | 0.631 |
| CD28 expression in EM CD4+ (MFI) | 8 | 1027.00 [890.00;1284.50] | 12 | 955.00 [802.50;1201.50] | 0.464 | 0.567 |
| EM CD4+ CD27+ CD28+(% of EM CD4+ T-cells) | 8 | 34.08 [26.25;42.46] | 12 | 31.17 [17.30;38.43] | 0.464 | 0.567 |
| CD27 expression in EM CD4+ CD27+CD28+ (MFI) | 8 | 1203.00 [1036.50;1389.00] | 12 | 1114.00 [971.00;1274.00] | 0.335 | 0.567 |
| CD28 expression in EM CD4+ CD27+CD28+ (MFI) | 8 | 1149.50 [1072.50;1365.50] | 12 | 1062.00 [874.00;1257.50] | 0.177 | 0.497 |
| EM CD4+ CD27+CD28- (% of EM CD4+ T-cells) | 8 | 0.18 [0.08;0.81] | 12 | 0.04 [0.00;0.32] | 0.241 | 0.497 |
| EM CD4+ CD27-CD28- (% of EM CD4+ T-cells) | 8 | 4.47 [0.92;13.05] | 12 | 2.19 [1.45;4.06] | 0.700 | 0.721 |
| EM CD4+ CD27-CD28+ (% of EM CD4+ T-cells) | 8 | 53.20 [50.65;61.83] | 12 | 62.95 [56.89;72.30] | 0.083 | 0.497 |
| EM CD4+ CD57+ (% of EM CD4+ T-cells) | 8 | 1.54 [0.74;3.57] | 12 | 2.14 [1.37;11.21] | 0.203 | 0.497 |
| TEMRA CD4+(% of CD4+ T-cells) | 8 | 0.41 [0.20;1.47] | 12 | 0.62 [0.33;2.60] | 0.375 | 0.567 |
| CD27 expression in TEMRA CD4+ (MFI) | 8 | 500.50 [95.500;697.50] | 9 | 396.00 [201.00;418.00] | 0.597 | 0.656 |
| CD28 expression in TEMRA CD4+ (MFI) | 8 | 519.00 [230.50;733.50] | 12 | 799.50 [455.00;1068.50] | 0.177 | 0.497 |
| TEMRA CD4+ CD27+CD28+ (% of TERMA CD4+ T-cells) | 8 | 26.935[11.58;48.75] | 12 | 27.59 [13.65;35.75] | 0.728 | 0.728 |
| CD27 expression in TEMRA CD4+ CD27+CD28+ (MFI) | 8 | 1189.50 [939.50;1464.50] | 12 | 1044.50 [937.00;1229.00] | 0.464 | 0.567 |
| CD28 expression in TEMRA CD4+ CD27+CD28+ (MFI) | 8 | 1007.00 [929.00;1082.00] | 12 | 1104.00 [816.00;1208.00] | 0.616 | 0.656 |
| TEMRA CD4+ CD27+CD28- (% of TEMRA CD4+ T-cells) | 8 | 10.42 [4.09;19.63] | 12 | 0.00 [0.00;1.88] | ***0.009*** | 0.283 |
| TEMRA CD4+ CD27-CD28- (% of TEMRA CD4+ T-cells) | 8 | 24.13 [11.51;53.79] | 12 | 12.95 [5.33;35.81] | 0.418 | 0.567 |
| TEMRA CD4+ CD57+ (% of TEMRA CD4+ T-cells) | 8 | 47.02 [28.37;76.66] | 12 | 27.99 [8.55;53.71] | 0.263 | 0.511 |
| **PBMC - CD8 Subsets** |  |  |  |  |  |  |
| Naïve CD8+ (% of CD8+ T-cells) | 8 | 8.89 [6.98;26.00] | 12 | 20.00 [14.10;48.67] | 0.083 | 0.195 |
| CD27 expression in Naïve CD8+ (MFI) | 8 | 1873.50 [1517.00;2110.50] | 12 | 1229.50 [1014.00;1579.00] | ***0.010*** | 0.064 |
| CD28 expression in Naïve CD8+ (MFI) | 8 | 642.50 [541.50;737.50] | 12 | 538.00 [436.00;641.00] | 0.177 | 0.278 |
| Naïve CD8+ CD27+ CD28+ (% of Naïve CD8+ T-cells) | 8 | 88.32 [76.96;91.95] | 12 | 66.27 [46.33;77.72] | ***0.004*** | 0.064 |
| CD27 expression in Naïve CD8+ CD27+CD28+ (MFI) | 8 | 2005.00 [1706.50;2230.50] | 12 | 1579.00 [1526.50;1820.50] | ***0.041*** | 0.148 |
| CD28 expression in Naïve CD8+ CD27+CD28+ (MFI) | 8 | 657.00 [558.00;770.00] | 12 | 576.50 [491.50;661.50] | 0.335 | 0.442 |
| Naïve CD8+ CD57+ (% of Naïve CD8+ T-cells) | 8 | 3.16 [1.80;7.34] | 12 | 5.19 [2.72;6.86] | 0.671 | 0.821 |
| CM CD8+ (% of CD8+ T-cells) | 8 | 17.90 [16.32;25.91] | 12 | 29.27 [22.16;39.40] | 0.059 | 0.176 |
| CD27 expression in CM CD8+ (MFI) | 8 | 1335.50 [1083.50;1461.00] | 12 | 905.50 [694.50;1069.00] | ***0.006*** | 0.064 |
| CD28 expression in CM CD8+ (MFI) | 8 | 1015.50 [896.00;1078.50] | 12 | 878.50 [691.00;1015.00] | 0.177 | 0.278 |
| CM CD8+ CD27+ CD28+ (% of CM CD8+ T-cells) | 8 | 74.34 [69.93;84.43] | 12 | 56.80 [45.18;66.45] | ***0.002*** | 0.064 |
| CD27 expression in CM CD8+ CD27+CD28+ (MFI) | 8 | 1589.50 [1382.00;1715.00] | 12 | 1323.50 [1172.00;1497.50] | ***0.041*** | 0.148 |
| CD28 expression in CM CD8+ CD27+CD28+ (MFI) | 8 | 1057.50 [942.50;1103.00] | 12 | 956.50 [775.00;1057.00] | 0.203 | 0.305 |
| CM CD8+ CD57+ (% of CM CD8+ T-cells) | 8 | 10.78 [8.77;12.74] | 12 | 9.92 [6.56;14.91] | 0.729 | 0.859 |
| EM CD8+ (% of CD8+ T-cells) | 8 | 30.36 [24.22;41.33] | 12 | 17.33 [10.72;28.47] | 0.070 | 0.192 |
| CD27 expression in EM CD8+ (MFI) | 8 | 631.00 [481.00;708.00] | 12 | 437.50 [357.00;578.50] | 0.097 | 0.214 |
| CD28 expression in EM CD8+ (MFI) | 8 | 474.50 [327.00;622.50] | 12 | 497.50 [396.50;591.00] | 0.847 | 0.932 |
| EM CD8+ CD27+ CD28+(% of EM CD8+ T-cells) | 8 | 23.70 [15.16;33.40] | 12 | 15.30 [8.64;23.33] | 0.083 | 0.195 |
| CD27 expression in EM CD8+ CD27+CD28+ (MFI) | 8 | 1369.50 [1297.00;1500.00] | 12 | 1274.50 [1211.00;1414.50] | 0.165 | 0.278 |
| CD28 expression in EM CD8+ CD27+CD28+ (MFI) | 8 | 819.50 [793.00;950.50] | 12 | 791.00 [732.00;899.50] | 0.512 | 0.650 |
| EM CD8+ CD27+CD28- (% of EM CD8+ T-cells) | 8 | 4.95 [3.01;6.91] | 12 | 2.16 [0.85;3.14] | ***0.028*** | 0.131 |
| EM CD8+ CD27-CD28- (% of EM CD8+ T-cells) | 8 | 27.68 [22.95;43.91] | 12 | 24.00 [12.54;40.40] | 0.335 | 0.442 |
| EM CD8+ CD27-CD28+ (% of EM CD8+ T-cells) | 8 | 36.82 [31.41;44.71] | 12 | 56.06 [42.69;64.97] | ***0.012*** | 0.067 |
| EM CD8+ CD57+ (% of EM CD8+ T-cells) | 8 | 44.74 [43.34;53.29] | 12 | 49.35 [15.50;60.11] | 0.847 | 0.932 |
| TEMRA CD8+(% of CD8+ T-cells) | 8 | 27.01 [18.18;39.86] | 12 | 22.32 [6.91;26.87] | 0.177 | 0.278 |
| CD27 expression in TEMRA CD8+ (MFI) | 8 | 257.50 [205.00;438.50] | 12 | 268.50 [195.50;386.00] | 0.877 | 0.934 |
| CD28 expression in TEMRA CD8+ (MFI) | 8 | 86.00 [67.00;132.50] | 12 | 188.00 [105.00;354.00] | ***0.045*** | 0.148 |
| TEMRA CD8+ CD27+CD28+ (% of TERMA CD8+ T-cells) | 8 | 4.33 [2.76;5.20] | 12 | 3.60 [1.80;6.91] | 0.908 | 0.936 |
| CD27 expression in TEMRA CD8+ CD27+CD28+ (MFI) | 8 | 1481.50 [1392.00;1560.50] | 11 | 1515.00 [1303.00;1664.00] | 1.000 | 1.000 |
| CD28 expression in TEMRA CD8+ CD27+CD28+ (MFI) | 8 | 685.50 [655.00;726.00] | 11 | 747.00 [653.00;873.00] | 0.231 | 0.332 |
| TEMRA CD8+ CD27+CD28- (% of TEMRA CD8+ T-cells) | 8 | 2.82 [2.26;4.50] | 12 | 1.30 [0.42;1.54] | ***0.010*** | 0.064 |
| TEMRA CD8+ CD27-CD28- (% of TEMRA CD8+ T-cells) | 8 | 81.72 [72.29;85.97] | 12 | 65.24 [43.68;81.82] | 0.133 | 0.273 |
| TEMRA CD8+ CD57+ (% of TEMRA CD8+ T-cells) | 8 | 73.62 [64.18;77.01] | 12 | 61.92 [39.21;76.18] | 0.154 | 0.278 |
| **PBMC - Tregs** |  |  |  |  |  |  |
| Total Treg (% of CD4+ T-cells) | 8 | 5.11 [4.28;6.19] | 12 | 4.57 [3.88;6.90] | 0.787 | 0.787 |
| CD25 expression in Total Treg (MFI) | 8 | 2203.50 [1610.00;2842.50] | 12 | 1293.50 [1096.50;1816.50] | ***0.041*** | 0.075 |
| CTLA-4 expression in Total Treg (MFI) | 8 | 228.50 [213.50;247.00] | 12 | 272.50 [246.50;301.00] | ***0.031*** | 0.075 |
| Naïve Treg (% of total Tregs) | 8 | 6.30 [4.76;8.05] | 12 | 5.15 [3.04;13.94] | 0.787 | 0.787 |
| CD25 expression of Naïve Treg (MFI) | 8 | 2048.50 [1173.50;2256.00] | 12 | 1279.50 [827.50;1556.50] | 0.059 | 0.081 |
| CTLA-4 expression of Naïve Treg (MFI) | 8 | 186.00 [178.50;220.00] | 12 | 252.50 [216.50;318.50] | ***0.025*** | 0.075 |
| Naïve Treg CTLA-4+ (% of Naïve Tregs) | 8 | 15.94 [8.51;19.89] | 12 | 33.18 [23.25;40.31] | ***0.025*** | 0.075 |
| Memory Treg (% of total Tregs) | 8 | 93.51 [91.47;94.70] | 12 | 94.74 [85.54;96.79] | 0.787 | 0.787 |
| CD25 expression of Memory Treg (MFI) | 8 | 2178.00 [1627.50;2838.50] | 12 | 1345.00 [1094.50;1845.50] | ***0.037*** | 0.075 |
| CTLA-4 expression of Memory Treg (MFI) | 8 | 230.50 [215.50;256.50] | 12 | 271.00 [248.00;305.00] | ***0.049*** | 0.077 |
| Memory Treg CTLA-4+ (% of Memory Tregs) | 8 | 15.59 [8.43;17.68] | 12 | 19.74 [16.52;21.61] | ***0.019*** | 0.075 |
| **PBMC – T-cell activation status** |  |  |  |  |  |  |
| CD4+ PD1+ (% of CD4+ T-cells) | 8 | 1.95 [1.69;2.89] | 12 | 1.26 [0.88;1.62] | ***0.049*** | 0.147 |
| PD1 expression in CD4+ (MFI) | 8 | 224.50 [160.50;297.00] | 12 | 195.50 [99.50;216.00] | 0.133 | 0.289 |
| CD4+ CD69+ (% of CD4+ T-cells) | 8 | 35.46 [25.93;42.24] | 12 | 31.54 [17.07;38.34] | 0.177 | 0.327 |
| CD69 expression in CD4+ (MFI) | 8 | 249.50 [236.00;290.50] | 12 | 262.00 [226.50;270.00] | 0.877 | 0.908 |
| CD4+ PD1+CD69+ (% of CD4+ T-cells) | 8 | 1.41 [0.98;2.13] | 12 | 0.74 [0.50;1.04] | ***0.023*** | 0.110 |
| CD4+ PD1-CD69- (% of CD4+ T-cells) | 8 | 64.00 [56.19;73.22] | 12 | 67.83 [61.28;82.28] | 0.177 | 0.327 |
| CD4+ HLADR+ (% of CD4+ T-cells) | 8 | 8.37 [6.88;14.41] | 12 | 16.98 [11.69;22.80] | ***0.034*** | 0.136 |
| HLADR expression in CD4+ (MFI) | 8 | 333.00 [297.50;381.00] | 12 | 459.00 [388.00;627.00] | ***0.023*** | 0.110 |
| CD4+ CD38+ (% of CD4+ T-cells) | 8 | 33.65 [18.60;46.64] | 12 | 28.78 [20.25;45.58] | 0.908 | 0.908 |
| CD38 expression in CD4+ (MFI) | 8 | 671.00 [500.00;874.00] | 12 | 644.50 [488.50;777.00] | 0.671 | 0.732 |
| CD4+ HLADR+CD38+ (% of CD4+ T-cells) | 8 | 2.41 [1.40;3.89] | 12 | 3.47 [2.14;4.28] | 0.354 | 0.532 |
| CD4+ HLADR-CD38- (% of CD4+ T-cells) | 8 | 59.02 [44.86;69.63] | 12 | 51.84 [48.00;63.98] | 0.563 | 0.711 |
| CD8+ PD1+ (% of CD8+ T-cells) | 8 | 29.14 [21.31;40.55] | 12 | 15.24 [9.90;23.11] | ***0.015*** | 0.110 |
| PD1 expression in CD8+ (MFI) | 8 | 325.00 [230.00;526.00] | 12 | 267.50 [203.50;323.50] | 0.263 | 0.421 |
| CD8+ CD69+ (% of CD8+ T-cells) | 8 | 36.86 [21.01;55.88] | 12 | 31.63 [22.80;42.70] | 0.464 | 0.655 |
| CD69 expression in CD8+ (MFI) | 8 | 513.00 [390.50;931.50] | 12 | 342.50 [279.50;437.00] | ***0.015*** | 0.110 |
| CD8+ PD1+CD69+ (% of CD8+ T-cells) | 8 | 11.68 [7.68;15.99] | 12 | 6.17 [5.13;9.99] | 0.076 | 0.202 |
| CD8+ PD1-CD69- (% of CD8+ T-cells) | 8 | 36.20 [30.95;53.39] | 12 | 58.50 [47.46;69.09] | ***0.023*** | 0.110 |
| CD8+ HLADR+ (% of CD8+ T-cells) | 8 | 31.78 [16.88;42.36] | 12 | 41.85 [33.45;47.17] | 0.133 | 0.289 |
| HLADR expression in CD8+ (MFI) | 8 | 474.50 [341.00;488.00] | 12 | 531.50 [489.50;709.00] | ***0.041*** | 0.140 |
| CD8+ CD38+ (% of CD8+ T-cells) | 8 | 14.06 [7.27;17.44] | 12 | 8.47 [6.20;21.45] | 0.671 | 0.732 |
| CD38 expression in CD8+ (MFI) | 8 | 293.00 [230.50;342.50] | 12 | 243.50 [192.50;355.00] | 0.563 | 0.711 |
| CD8+ HLADR+CD38+ (% of CD8+ T-cells) | 8 | 7.82 [1.71;10.11] | 12 | 4.98 [4.12;6.99] | 0.671 | 0.732 |
| CD8+ HLADR-CD38- (% of CD8+ T-cells) | 8 | 64.70 [38.71;77.09] | 12 | 52.45 [48.44;55.66] | 0.203 | 0.348 |
| **Plasma - Essential Immune Response** |  |  |  |  |  |  |
| IL-4 (pg/mL) | 8 | 0.11 [0.00;28.48] | 12 | 0.06 [0.00;1.38] | 0.773 | 0.928 |
| IL-2 (pg/mL) | 8 | 3.34 [1.92;9.66] | 12 | 1.80 [0.67;2.24] | 0.154 | 0.423 |
| CXCL-10 (IP-10) (pg/mL) | 8 | 159.08 [125.71;355.70] | 12 | 311.58 [176.37;354.14] | 0.232 | 0.423 |
| IL-1 beta (pg/mL) | 8 | 6.06 [1.47;34.62] | 12 | 5.27 [0.77;11.90] | 0.616 | 0.858 |
| TNF alpha (pg/mL) | 8 | 1.81 [1.21;5.54] | 12 | 2.07 [1.63;3.43] | 0.643 | 0.858 |
| CCL2 (MCP-1) (pg/mL) | 8 | 193.48 [149.28;232.19] | 12 | 133.65 [97.65;174.79] | 0.070 | 0.419 |
| IL-17A (pg/mL) | 8 | 2.23 [1.18;22.16] | 12 | 2.78 [1.35;8.50] | 0.969 | 0.969 |
| IL-6 (pg/mL) | 8 | 8.40 [3.86;24.28] | 12 | 3.86 [2.88;8.14] | 0.203 | 0.423 |
| IL-10 (pg/mL) | 8 | 2.23 [1.54;3.82] | 12 | 1.37 [0.62;2.63] | 0.247 | 0.423 |
| IFN gamma (pg/mL) | 8 | 0.91 [0.00;35.63] | 12 | 1.32 [0.00;6.07] | 0.905 | 0.969 |
| IL-12p70 (pg/mL) | 8 | 6.93 [4.28;58.97] | 12 | 2.05 [0.71;4.19] | ***0.008*** | 0.093 |
| CXCL-8 (IL-8) (pg/mL) | 8 | 7.23 [3.55;25.42] | 12 | 3.77 [1.94;11.62] | 0.232 | 0.423 |
| **Plasma - Immune Checkpoint** |  |  |  |  |  |  |
| sCD25 (IL-2Ra) (pg/mL) | 8 | 928.26 [798.87;1140.80] | 12 | 1504.50 [978.83;2268.00] | 0.133 | 0.531 |
| 4-1BB (pg/mL) | 8 | 68.07 [50.57;119.55] | 12 | 80.31 [54.40;156.65] | 0.464 | 0.695 |
| sCD27 (pg/mL) | 8 | 52670.00 [45645.00;65276.00] | 12 | 66274.00 [50880.00;87801.00] | 0.298 | 0.595 |
| B7.2 (CD86) (pg/mL) | 8 | 524.80 [474.15;697.47] | 12 | 582.31 [452.28;700.38] | 0.969 | 0.969 |
| Free Active TGF-B1 (pg/mL) | 8 | 25.39 [22.12;32.09] | 12 | 23.19 [11.09;42.99] | 0.616 | 0.821 |
| CTLA-4 (pg/mL) | 8 | 10.14 [4.40;15.98] | 12 | 8.84 [2.25;27.96] | 0.847 | 0.924 |
| PD-L1 (pg/mL) | 8 | 279.06 [172.00;401.70] | 12 | 165.63 [113.50;213.15] | 0.154 | 0.531 |
| PD-L2 (pg/mL) | 8 | 11121.00 [10196.00;14318.00] | 12 | 13370.00 [11972.00;16020.00] | 0.177 | 0.531 |
| PD-1 (pg/mL) | 8 | 92.41 [16.51;201.92] | 12 | 33.25 [16.94;118.63] | 0.787 | 0.924 |
| Tim-3 (pg/mL) | 8 | 15345.00 [6568.40;26546.00] | 12 | 26074.00 [18660.00;38595.00] | 0.114 | 0.531 |
| LAG-3 (pg/mL) | 8 | 5456.70 [2198.80;16183.00] | 12 | 2560.40 [1596.90;3621.40] | 0.263 | 0.595 |
| Gal-9 (pg/mL) | 8 | 102158.00 [76361.00;127351.00] | 12 | 1058680.00 [90925.00;159163.00] | 0.375 | 0.643 |